Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jul 7, 2013; 19(25): 3931-3941
Published online Jul 7, 2013. doi: 10.3748/wjg.v19.i25.3931
Published online Jul 7, 2013. doi: 10.3748/wjg.v19.i25.3931
Why interleukin-10 supplementation does not work in Crohn’s disease patients
Gareth J Marlow, Dominique van Gent, Lynnette R Ferguson, Discipline of Nutrition, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand
Gareth J Marlow, Lynnette R Ferguson, Nutrigenomics New Zealand, The University of Auckland, Auckland 1142, New Zealand
Author contributions: All authors contributed equally to this paper.
Supported by The Ministry of Business, Innovation and Employment; Dutch Digestive Foundation
Correspondence to: Lynnette R Ferguson, Professor, Discipline of Nutrition, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand. l.ferguson@auckland.ac.nz
Telephone: +64-9-9236372 Fax: +64-9-3035962
Received: February 28, 2013
Revised: April 18, 2013
Accepted: May 8, 2013
Published online: July 7, 2013
Revised: April 18, 2013
Accepted: May 8, 2013
Published online: July 7, 2013
Core Tip
Core tip: Inflammatory bowel disease (IBD) is a chronic condition with no known cure. This review addresses the current available treatments for IBD before discussing a potential new treatment strategy using the immunoregulatory cytokine interleukin-10 (IL-10). To date clinical trial results have been disappointing. We highlight the limitations of current IL-10 supplementation treatment and suggest how, with changes to IL-10 delivery and the correct choice of patient, IL-10 supplementation could become a viable treatment option.